Current Report Filing (8-k)
19 Januar 2023 - 12:02PM
Edgar (US Regulatory)
0001716947
false
0001716947
2023-01-18
2023-01-18
0001716947
ENSC:CommonStockParValue0.0001PerMember
2023-01-18
2023-01-18
0001716947
ENSC:WarrantsToPurchaseOneShareOfMember
2023-01-18
2023-01-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 18, 2023 (January 18, 2023)
Ensysce
Biosciences, Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-38306 |
|
82-2755287 |
(State
or other jurisdiction of
incorporation
or organization) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
Number) |
7946
Ivanhoe Avenue, Suite 201
La
Jolla, California |
|
92037 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(858)
263-4196
Registrant’s
telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
|
ENSC |
|
The
Nasdaq Stock Market LLC |
Warrants
to purchase one share of Common Stock |
|
ENSCW |
|
OTC
Pink Open Market |
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
On
January 18, 2023, Ensysce Biosciences, Inc. delivered a presentation entitled “Improving Prescription Drug Safety Through Chemistry”
to investors. A copy of the presentation is filed as Exhibit 99 to this Current Report on Form 8-K and is incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
January 18, 2023
|
Ensysce
Biosciences, Inc. |
|
|
|
|
By: |
/s/
Lynn Kirkpatrick |
|
Name:
|
Dr.
Lynn Kirkpatrick |
|
Title: |
President
and Chief Executive Officer |
Leisure Acquisition (NASDAQ:LACQ)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Leisure Acquisition (NASDAQ:LACQ)
Historical Stock Chart
Von Jun 2023 bis Jun 2024